In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to Bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success?
